Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $9M | $-80M | $-81M | $-82M | -29.6% | - | 13.4% |
| 2024 | $0M | $-69M | $-71M | $-52M | -22.0% | - | 11.4% |
| 2023 | $0M | $-56M | $-64M | $-38M | 36.8% | - | 60.8% |
| 2022 | $0M | $-39M | $-40M | $-36M | 35.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 8.99 |
| Operating Revenue | 0 | 0 | 0 | 8.99 |
| Operating Expense | 39.97 | 48.40 | 78.19 | 101.78 |
| Research And Development | 30.52 | 33.89 | 59.04 | 73.97 |
| Selling General And Administration | 9.45 | 14.51 | 19.16 | 27.81 |
| Total Expenses | 39.97 | 48.40 | 78.19 | 101.78 |
| Operating Income | -39.97 | -48.40 | -78.19 | -92.78 |
| Total Operating Income As Reported | -39.97 | -48.40 | -78.19 | -92.78 |
| EBITDA | -39.35 | -55.90 | -68.58 | -79.69 |
| Normalized EBITDA | -39.38 | -45.81 | -68.40 | -79.48 |
| EBIT | -39.48 | -56.06 | -68.74 | -79.91 |
| Interest Income | 0.46 | 2.43 | 9.63 | 13.09 |
| Interest Expense | 0.24 | 7.79 | 2.37 | 0.70 |
| Net Interest Income | 0.22 | -5.36 | 7.26 | 12.39 |
| Other Income Expense | 0.02 | -10.09 | -0.18 | -0.21 |
| Interest Income Non Operating | 0.46 | 2.43 | 9.63 | 13.09 |
| Interest Expense Non Operating | 0.24 | 7.79 | 2.37 | 0.70 |
| Net Non Operating Interest Income Expense | 0.22 | -5.36 | 7.26 | 12.39 |
| Pretax Income | -39.72 | -63.85 | -71.11 | -80.60 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income From Continuing And Discontinued Operation | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income From Continuing Operation Net Minority Interest | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income Common Stockholders | -39.72 | -63.85 | -71.11 | -80.60 |
| Net Income Including Noncontrolling Interests | -39.72 | -63.85 | -71.11 | -80.60 |
| Normalized Income | -39.74 | -53.76 | -70.93 | -80.39 |
| Diluted NI Availto Com Stockholders | -39.72 | -63.85 | -71.11 | -80.60 |
| Basic Average Shares | 1.67 | 20.12 | 10.73 | - |
| Diluted Average Shares | 1.67 | 20.12 | 10.73 | - |
| Reconciled Depreciation | 0.13 | 0.16 | 0.17 | 0.21 |
| Total Unusual Items | 0.02 | -10.09 | -0.18 | -0.21 |
| Total Unusual Items Excluding Goodwill | 0.02 | -10.09 | -0.18 | -0.21 |
| Special Income Charges | - | 0 | -0.25 | 0 |
| Other Special Charges | - | - | 0.25 | - |
| Gain On Sale Of Security | 0.02 | -10.09 | 0.07 | -0.21 |
| General And Administrative Expense | 9.45 | 14.51 | 19.16 | 27.81 |
| Other Gand A | 9.45 | 14.51 | 19.16 | 27.81 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioAge Labs, Inc.this co. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M | -3.55 | -1.79 | 50.5% | -5.69 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| Geron Corporation | GERN | $776M |
| -9.30 |
| 3.44 |
| -37.0% |
| -16.53 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Peer Median | - | -10.82 | 3.53 | -16.2% | -7.97 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jun has averaged the highest return (+23.0%); Jul the lowest (-28.3%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +43.5%Positive MonthJan 2026: +43.54% | +17.3%Positive MonthFeb 2026: +17.27% | -21.5%Negative MonthMar 2026: -21.46% | -3.7%Negative MonthApr 2026: -3.66% | +2.6%Positive MonthMay 2026: +2.61% | +41.8%Positive MonthJun 2026: +41.76% | -63.1%Negative MonthJul 2026: -63.12% | +18.9%*Positive MonthAug 2026: +18.92% | — | — | — | — |
| 2025 | -20.7%Negative MonthJan 2025: -20.73% | +0.9%Neutral MonthFeb 2025: +0.87% | -18.8%Negative MonthMar 2025: -18.79% | +11.7%Positive MonthApr 2025: +11.70% | -5.7%Negative MonthMay 2025: -5.71% | +4.3%Positive MonthJun 2025: +4.29% | +6.5%Positive MonthJul 2025: +6.54% | +12.0%Positive MonthAug 2025: +12.05% | +19.3%Positive MonthSep 2025: +19.27% | +28.7%Positive MonthOct 2025: +28.74% | +25.4%Positive MonthNov 2025: +25.36% | +39.4%Positive MonthDec 2025: +39.41% |
| 2024 | — | — | — | — | — | — | — | — | — | +13.5%Positive MonthOct 2024: +13.46% | -20.3%Negative MonthNov 2024: -20.34% | -69.2%Negative MonthDec 2024: -69.20% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 3 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
